InvestorsHub Logo
Post# of 596784
Next 10
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Re: None

Friday, 09/16/2016 10:34:42 AM

Friday, September 16, 2016 10:34:42 AM

Post# of 596784
$RGBP HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.

Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



http://www.regenbiopharmainc.com/product-pipeline.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.